Endometrial Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with low-risk endometrial (uterine) cancer of a specific type called endometrioid, graded as grade 1 or 2, and classified as an early stage (stage IA under older staging guidelines, or stages IA1/IA2 under newer guidelines)
- People whose cancer shows no significant spread into blood or lymph vessels — specifically, fewer than 5 vessels involved (a small amount of vessel involvement, called focal LVSI, is acceptable)
- People who have had complete surgical staging, including a specific lymph node procedure called a sentinel lymph node biopsy, carried out according to established medical guidelines
- People whose sentinel lymph node results showed only a very tiny amount of cancer cells — a cluster of 0.2mm or smaller, or fewer than 200 cells (this is called an isolated tumour cell, or ITC finding)
- People who have not received any additional cancer treatment after surgery
- People who have provided consent to participate in research
Who may not be able to join:
- People who received chemotherapy before their surgery
- People who are planning to receive any additional cancer treatment after surgery
- People who currently have another active cancer (skin cancers other than melanoma are exempt from this rule)
- People whose sentinel lymph node results showed a larger amount of cancer spread — either micrometastasis (0.2mm to 2.0mm) or macrometastasis (larger than 2.0mm)
- People whose final surgical results showed significant spread into 5 or more blood or lymph vessels
- People who have been diagnosed with another invasive cancer within the past 5 years (skin cancers other than melanoma are exempt from this rule)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Gretchen E. Glaser, MD, Mayo Clinic in Rochester
Phone: 855-776-0015
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Recurrence-free survival (RFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.